Dr. Reddy’s selling anti-cancer agent to Citius Pharma

Set to receive $40 million upfront, approval milestone payment of upto $40 million later

Dr. Reddy’s Laboratories has entered into a definitive agreement with Citius Pharmaceuticals Inc pursuant to which it sold all rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets.

In March 2016, it had acquired the exclusive global rights, excluding Japan and Asia, to the investigational anti-cancer agent E7777 from Eisai Co.


Under the agreement with Citius, Dr. Reddy’s will receive $40 million upfront on closing of the transaction followed by approval milestone payment of upto $40 million related to the CTCL (cutaneous T-cell lymphoma) indication approval and upto $70 million for additional indication approvals. Further, it will receive certain sales-based milestones and tiered earn-out payments, the Hyderabad-based drugmaker said in a release on Saturday.

E7777 has significant potential as an important component of systemic therapy for CTCL and other cancers. After acquiring it from Eisai, significant progress was made on the CTCL development front, CEO Erez Israeli said. “We are confident of Citius’ ability to realize the full potential of E7777 in the treatment of CTCL as well as in their ability to develop this promising drug for additional oncology and immuno-oncology indications,” he said.

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook


We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Education News Click Here 

 For the latest news and updates, follow us on Google News


Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.